Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease
Canadian Journal of Gastroenterology and Hepatology · 08.11.2022 · 2022 · 1-18
DOI: 10.1155/2022/6799414 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, erschienen am 08.11.2022. Verfasst von Bing Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Pre…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical and Health Appropriate Technology Development, Promotion and Application Project of Guangxi, National Institutes of Health.
Abstract (Originalsprache)
The pathogenesis of NAFLD is complex and diverse, involving multiple signaling pathways and cytokines from various organs. Hepatokines, stellakines, adipokines, and myokines secreted by hepatocytes, hepatic stellate cells, adipose tissue, and myocytes play an important role in the occurrence and development of nonalcoholic fatty liver disease (NAFLD). The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) contributes to the progression of NAFLD by mediating liver inflammation, immune response, hepatocyte death, and later compensatory proliferation. In this review, we first discuss the crosstalk and interaction between hepatokines, stellakines, adipokines, and myokines and NF-κB in NAFLD. The characterization of the crosstalk of NF-κB with these factors will provide a better understanding of the molecular mechanisms involved in the progression of NAFLD. In addition, we examine new expert management opinions for NAFLD and explore the therapeutic potential of silymarin in NAFLD/NASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Endocrinology and Metabolism, Guangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, Guangxi Clinical Research Center for Cardio-Cerebrovascular D…
- Department of Gastroenterology and Thoracic Surgery, Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
- Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- Northwestern Medicine Organ Transplantation Center, Arkes Pavilion, Chicago, IL 60611, USA.
ORCID-Profile: Xi Yang, Heping Yang
Förderung
- Medical and Health Appropriate Technology Development, Promotion and Application Project of Guangxi
- National Institutes of Health
Zitieren
APA
Yang, B., Yang, X., Tan, X., Lu, L., Fan, W., Barbier-Torres, L., Steggerda, J., Liu, T., & Yang, H. (2022). Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2022, 1-18. https://doi.org/10.1155/2022/6799414
Vancouver
Yang B, Yang X, Tan X, Lu L, Fan W, Barbier-Torres L, et al. Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology. 2022;2022:1-18. doi:10.1155/2022/6799414
BibTeX
@article{Yang2022,
author = {Yang, Bing and Yang, Xi and Tan, Xumei and Lu, Liqing and Fan, Wei and Barbier-Torres, Lucía and Steggerda, Justin and Liu, Ting and Yang, Heping},
title = {Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2022},
volume = {2022},
pages = {1--18},
doi = {10.1155/2022/6799414}
}
EUVIMED